TG Therapeutics Raises 2026 Revenue Guidance Following Strong BRIUMVI Sales

TG Therapeutics (TGTX) has raised its full-year 2026 global revenue guidance to approximately $1 billion, driven by significant commercial momentum for its B-cell targeting therapy, BRIUMVI. Third-quarter U.S. net product revenue for BRIUMVI grew 52% year-over-year, reaching $233 million, providing the company with strong operating cash flow to fund clinical pipeline expansion. The company is focusing on two key growth drivers: a new subcutaneous formulation that could more than double peak sales opportunities by capturing the self-administration market, and a streamlined single-dose IV initiation process expected to drive demand in late 2027. With patent protection extending into the mid-2040s and $557 million in cash reserves, TG Therapeutics is positioned for long-term expansion in the multiple sclerosis treatment market.

By The Motley Fool Team · Motley Fool ·

TG Therapeutics Raises 2026 Revenue Guidance Following Strong BRIUMVI Sales

Tickers: $TGTX

Topics: biotechnology multiple sclerosis treatment quarterly earnings revenue guidance

Read the full article at Motley Fool

More World news